-agent tivozanib in patients with platinum-resistant ovarian cancer Contact: Nikki Neubauer, MD • 312-472-4684 Rachel Bers, BS • 312-472-5726 • r-bers@northwestern.edu ClinicalTrials.gov Identifier: NCT01853644 Phase I Trial of Intraperitoneal Nab-Paclitaxel
Search Results
F. Anthony Greco
Med 2004 ; 350 : 2335 – 2342 . 4. Sandler AB Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer . N Engl J Med 2006 ; 355 : 2542 – 2550 . 5. Moore MJ Goldstein D Hamm J . Erlotinib
Athanassios Argiris
-fluoruracil (F) versus P, F and paclitaxel (T) as induction therapy in locally advanced head & neck cancer (LAHNC) (Abstr) . Proc Am Soc Clin Oncol 2003 ; 22 : A1997 . 8 Vermorken JB Remenar E Van Herpen C . Standard cisplatin/infusional 5
Leora Horn
in Oncology (NCCN Guidelines) for NSCLC, many chemotherapy drugs are useful for treating patients with advanced-stage NSCLC. Among them are platinum agents (eg, cisplatin, carboplatin), taxanes (eg, paclitaxel, albumin-bound paclitaxel, docetaxel
Maurie Markman
: 4265 – 4269 . 16 Francis P Rowinsky E Schneider J . Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study . J Clin Oncol 1995 ; 13 : 2961 – 2967 . 17 Markman
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone
single agents in the metastatic disease setting based on several randomized phase III trials. 18 , 19 Cisplatin is a standard backbone of combination chemotherapy regimens, and cisplatin-based chemotherapy regimens (eg, cisplatin/paclitaxel
Matthieu Picard, Ursula A. Matulonis, and Mariana Castells
doxorubicin (PLD) seems to significantly reduce the incidence of HSRs attributable to carboplatin compared with administering carboplatin as a single agent or in combination with paclitaxel. 31 , 32 The effect of PLD on reducing carboplatin-related infusion
Neelima Vidula, Leif W. Ellisen, and Aditya Bardia
III study compared veliparib with carboplatin and paclitaxel followed by maintenance veliparib versus chemotherapy in germline BRCA1/2 -mutant HER2-negative advanced breast cancer. 18 Median PFS improved from 12.6 to 14.5 months with the addition of
Dipesh Uprety and David E. Marinier
used for concurrent CRT, including cisplatin/etoposide, carboplatin/paclitaxel, cisplatin/vinblastine, and, for nonsquamous pathology, carboplatin or cisplatin with pemetrexed. 7 The carboplatin/paclitaxel regimen is given weekly with radiation therapy
Feng Lin, Jinlin Song, Melissa Pavilack, Jipan Xie, Catherine Fernan, Ahmed Noman, and Winghan Jacqueline Kwong
patients who used TBR as 1L, 130 initiated 2L treatment and trastuzumab was used again as 2L in 72 patients. The most common regimens used in 2L post 1L TBR were paclitaxel + ramucirumab (15.4%), FOLFOX + trastuzumab (11.5%), and capecitabine + trastuzumab
